Host defense peptides: Front-line immunomodulators

Trends in Immunology

Volumn 35, Issue 9, 2014, Pages 443-450

  Mansour, Sarah C ^a   Pena, Olga M ^a   Hancock, Robert E W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; HOST DEFENSE PEPTIDE; IMMUNOMODULATING AGENT; POLYPEPTIDE ANTIBIOTIC AGENT; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOPHAGY; BACTERICIDAL ACTIVITY; CELL DIFFERENTIATION; DRUG COST; DRUG SYNTHESIS; EXTRACELLULAR MATRIX; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; WOUND HEALING; ANIMAL; CHEMOTAXIS; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; APOPTOSIS; AUTOPHAGY; CHEMOTAXIS; HUMANS; IMMUNITY, INNATE; IMMUNOMODULATION; MOLECULAR TARGETED THERAPY;

EID: 84922565465     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2014.07.004     Document Type: Review

References (92)

1. Parker M.T., Hewitt J.H. Methicillin resistance in Staphylococcus aureus. Lancet 1970, 1:800-804.
2. Pendleton J.N., et al. Clinical relevance of the ESKAPE pathogens. Expert Rev. Anti Infect. Ther. 2013, 11:297-308.
3. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415:389-395.
4. Phoenix D.A., et al. Antimicrobial Peptides: Their History, Evolution, and Functional Promiscuity 2013, Wiley.
5. Hancock R.E., et al. Trends Biotechnol. 1998, 16:82-88.
6. Hale J.D., Hancock R.E. Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev. Anti Infect. Ther. 2007, 5:951-959.
7. Spindler E.C., et al. Deciphering the mode of action of the synthetic antimicrobial peptide Bac8c. Antimicrob. Agents Chemother. 2012, 55:1706-1716.
8. Fjell C.D., et al. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 2012, 11:37-51.
9. de la Fuente-Nunez C., et al. Broad-spectrum anti-biofilm peptide that targets a cellular stress response. PLoS Pathog. 2014, 10:e1004152.
10. Bowdish D.M., et al. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 2005, 77:451-459.
11. Herasimenka Y., et al. Interaction of antimicrobial peptides with bacterial polysaccharides from lung pathogens. Peptides 2005, 26:1127-1132.
12. Pena O.M., et al. Synthetic cationic peptide IDR-1018 modulates human macrophage differentiation. PLoS ONE 2013, 8:e52449.
13. Koczulla R., et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 2003, 111:1665-1672.
14. Yang D., et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286:525-528.
15. Hilchie A.L., et al. Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat. Chem. Biol. 2013, 9:761-768.
16. Amid C., et al. Manual annotation and analysis of the defensin gene cluster in the C57BL/6J mouse reference genome. BMC Genomics 2009, 10:606.
17. Arnett E., Seveau S. The multifaceted activities of mammalian defensins. Curr. Pharm. Des. 2011, 17:4254-4269.
18. Sorensen O.E., et al. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001, 97:3951-3959.
19. Fukumoto K., et al. Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats. Pediatr. Surg. Int. 2005, 21:20-24.
20. De Y., et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 2000, 192:1069-1074.
21. Putsep K., et al. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 2002, 360:1144-1149.
22. Nijnik A., et al. Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment. J. Immunol. 2010, 184:2539-2550.
23. Scott M.G., et al. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 2007, 25:465-472.
24. Achtman A.H., et al. Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria. Sci. Transl. Med. 2012, 4:135ra64.
25. Rivas-Santiago B., et al. Ability of innate defence regulator peptides IDR-1002, IDR-HH2 and IDR-1018 to protect against Mycobacterium tuberculosis infections in animal models. PLoS ONE 2013, 8:e59119.
26. Steinstraesser L., et al. Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS ONE 2012, 7:e39373.
27. Shestakov A., et al. Synthetic analogues of bovine bactenecin dodecapeptide reduce herpes simplex virus type 2 infectivity in mice. Antiviral Res. 2013, 100:455-459.
28. Bolouri H., et al. Innate defense regulator peptide 1018 protects against perinatal brain injury. Ann. Neurol. 2014, 75:395-3410.
29. Mookherjee N., et al. Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J. Immunol. 2006, 176:2455-2464.
30. Tjabringa G.S., et al. Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. Int. Arch. Allergy Immunol. 2006, 140:103-112.
31. Nijnik A., et al. Signaling pathways mediating chemokine induction in keratinocytes by cathelicidin LL-37 and flagellin. J. Innate Immun. 2012, 4:377-386.
32. Mantovani A., et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 2011, 11:519-531.
33. Niyonsaba F., et al. The innate defense regulator peptides IDR-HH2, IDR-1002, and IDR-1018 modulate human neutrophil functions. J. Leukoc. Biol. 2013, 94:159-170.
34. Davidson D.J., et al. The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J. Immunol. 2004, 172:1146-1156.
35. Heilborn J.D., et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 2003, 120:379-389.
36. Barlow P.G., et al. The human cathelicidin LL-37 preferentially promotes apoptosis of infected airway epithelium. Am. J. Respir. Cell Mol. Biol. 2010, 43:692-702.
37. Hu Z., et al. Antimicrobial cathelicidin peptide LL-37 inhibits the LPS/ATP-induced pyroptosis of macrophages by dual mechanism. PLoS ONE 2014, 9:e85765.
38. Rosenfeld Y., et al. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J. Biol. Chem. 2006, 281:1636-1643.
39. Scott M.G., et al. Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J. Immunol. 2000, 164:549-553.
40. Mookherjee N., et al. Intracellular receptor for human host defense peptide LL-37 in monocytes. J. Immunol. 2009, 183:2688-2696.
41. Nijnik A., et al. Human cathelicidin peptide LL-37 modulates the effects of IFN-gamma on APCs. J. Immunol. 2009, 183:5788-5798.
42. Yu J., et al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J. Immunol. 2007, 179:7684-7691.
43. Mookherjee N., Hancock R.E. Cationic host defence peptides: innate immune regulatory peptides as a novel approach for treating infections. Cell. Mol. Life Sci. 2007, 64:922-933.
44. Welling M.M., et al. Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. J. Clin. Invest. 1998, 102:1583-1590.
45. Madera L., Hancock R.E. Synthetic immunomodulatory peptide IDR-1002 enhances monocyte migration and adhesion on fibronectin. J. Innate Immun. 2012, 4:553-568.
46. Durr M., Peschel A. Chemokines meet defensins: the merging concepts of chemoattractants and antimicrobial peptides in host defense. Infect. Immun. 2002, 70:6515-6517.
47. Yang D., et al. Participation of mammalian defensins and cathelicidins in anti-microbial immunity: receptors and activities of human defensins and cathelicidin (LL-37). J. Leukoc. Biol. 2001, 69:691-697.
48. Yount N.Y., Yeaman M.R. Structural congruence among membrane-active host defense polypeptides of diverse phylogeny. Biochim. Biophys. Acta 2006, 1758:1373-1386.
49. von Kockritz-Blickwede M., et al. Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. Blood 2008, 111:3070-3080.
50. Overhage J., et al. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 2008, 76:4176-4182.
51. Biragyn A., et al. Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002, 298:1025-1029.
52. van der Does A.M., et al. The antimicrobial peptide hLF1-11 drives monocyte-dendritic cell differentiation toward dendritic cells that promote antifungal responses and enhance Th17 polarization. J. Innate Immun. 2012, 4:284-292.
53. Mantovani A., et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
54. Qin X.J., et al. CCL22 recruits CD4-positive CD25-positive regulatory T cells into malignant pleural effusion. Clin. Cancer Res. 2009, 15:2231-2237.
55. Kin N.W., et al. Cathelin-related antimicrobial peptide differentially regulates T- and B-cell function. Eur. J. Immunol. 2011, 41:3006-3016.
56. Hurtado P., Peh C.A. LL-37 promotes rapid sensing of CpG oligodeoxynucleotides by B lymphocytes and plasmacytoid dendritic cells. J. Immunol. 2010, 184:1425-1435.
57. Nicholls E.F., et al. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann. N. Y. Acad. Sci. 2010, 1213:46-61.
58. Kovacs-Nolan J., et al. CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle. Vaccine 2009, 27:2048-2054.
59. Brown T.H., et al. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection. Vaccine 2012, 30:350-360.
60. Shaykhiev R., et al. The antimicrobial peptide cathelicidin enhances activation of lung epithelial cells by LPS. FASEB J. 2010, 24. 4756-4766.
61. Tomioka H., et al. Novel anti-microbial peptide SR-0379 accelerates wound healing via the PI3 kinase/Akt/mTOR pathway. PLoS ONE 2014, 9:e92597.
62. Niyonsaba F., et al. Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines. J. Invest. Dermatol. 2007, 127:594-604.
63. Carretero M., et al. In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. J. Invest. Dermatol. 2008, 128:223-236.
64. Yin J., Yu F.S. LL-37 via EGFR transactivation to promote high glucose-attenuated epithelial wound healing in organ-cultured corneas. Invest. Ophthalmol. Vis. Sci. 2010, 51:1891-1897.
65. Yuk J.M., et al. Vitamin D3 induces autophagy in human monocytes/macrophages via cathelicidin. Cell Host Microbe 2009, 6:231-243.
66. Mayer M.L., et al. Rescue of dysfunctional autophagy attenuates hyperinflammatory responses from cystic fibrosis cells. J. Immunol. 2013, 190:1227-1238.
67. Kindrachuk J., et al. Stability, toxicity, and biological activity of host defense peptide BMAP28 and its inversed and retro-inversed isomers. Biopolymers 2011, 96:14-24.
68. Afacan N.J., et al. Therapeutic potential of host defense peptides in antibiotic-resistant infections. Curr. Pharm. Des. 2012, 18:807-819.
69. Bommarius B., et al. Cost-effective expression and purification of antimicrobial and host defense peptides in Escherichia coli. Peptides 2010, 31:1957-1965.
70. Bowdish D.M., et al. Immunomodulatory activities of small host defense peptides. Antimicrob. Agents Chemother. 2005, 49:1727-1732.
71. Niyonsaba F., et al. Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur. J. Immunol. 2001, 31:1066-1075.
72. Morizane S., et al. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands. J. Invest. Dermatol. 2012, 132:135-143.
73. Yamasaki K., et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat. Med. 2007, 13:975-980.
74. Yin L.M., et al. Roles of hydrophobicity and charge distribution of cationic antimicrobial peptides in peptide-membrane interactions. J. Biol. Chem. 2012, 287:7738-7745.
75. Mookherjee N., et al. Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells. Mol. Biosyst. 2009, 5:483-496.
76. Sieprawska-Lupa M., et al. Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob. Agents Chemother. 2004, 48:4673-4679.
77. Kim H., et al. De novo generation of short antimicrobial peptides with enhanced stability and cell specificity. J. Antimicrob. Chemother. 2014, 69:121-132.
78. Molhoek E.M., et al. Improved proteolytic stability of chicken cathelicidin-2 derived peptides by D-amino acid substitutions and cyclization. Peptides 2011, 32:875-880.
79. Sobczak M., et al. Polymeric systems of antimicrobial peptides - strategies and potential applications. Molecules 2013, 18:14122-14137.
80. Bevins C.L. Innate immune functions of alpha-defensins in the small intestine. Dig. Dis. 2013, 31:299-304.
81. Ouellette A.J. Paneth cell alpha-defensins in enteric innate immunity. Cell. Mol. Life Sci. 2011, 68:2215-2229.
82. Gursoy U.K., et al. Human neutrophil defensins and their effect on epithelial cells. J. Periodontol. 2013, 84:126-133.
83. Rupec R.A., et al. What is really in control of skin immunity: lymphocytes, dendritic cells, or keratinocytes? facts and controversies. Clin. Dermatol. 2010, 28:62-66.
84. Ferris L.K., et al. Human beta-defensin 3 induces maturation of human Langerhans cell-like dendritic cells: an antimicrobial peptide that functions as an endogenous adjuvant. J. Invest. Dermatol. 2013, 133:460-468.
85. Navid F., et al. Induction of regulatory T cells by a murine beta-defensin. J. Immunol. 2012, 188:735-743.
86. Semple F., Dorin J.R. Beta-defensins: multifunctional modulators of infection, inflammation and more?. J. Innate Immun. 2012, 4:337-348.
87. Vandamme D., et al. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell. Immunol. 2012, 280:22-35.
88. Salvado M.D., et al. Cathelicidin LL-37 induces angiogenesis via PGE2-EP3 signaling in endothelial cells, in vivo inhibition by aspirin. Arterioscler. Thromb. Vasc. Biol. 2013, 33:1965-1972.
89. Chen X., et al. Human antimicrobial peptide LL-37 modulates proinflammatory responses induced by cytokine milieus and double-stranded RNA in human keratinocytes. Biochem. Biophys. Res. Commun. 2013, 433:532-537.
90. Coffelt S.B., et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:3806-3811.
91. Krasnodembskaya A., et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010, 28:2229-2238.
92. Mader J.S., et al. The human cathelicidin, LL-37, induces granzyme-mediated apoptosis in regulatory T cells. J. Immunother. 2011, 34:229-235.